Comparative pathology, molecular pathogenicity, immunological features, and genetic characterization of three highly pathogenic human coronaviruses (MERS-CoV, SARS-CoV, and SARS-CoV-2)

Eur Rev Med Pharmacol Sci. 2021 Nov;25(22):7162-7184. doi: 10.26355/eurrev_202111_27270.ABSTRACTThe last two decades have witnessed the emergence of three deadly coronaviruses (CoVs) in humans: severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). There are still no reliable and efficient therapeutics to manage the devastating consequences of these CoVs. Of these, SARS-CoV-2, the cause of the currently ongoing coronavirus disease 2019 (COVID-19) pandemic, has posed great global health concerns. The COVID-19 pandemic has resulted in an unprecedented crisis with devastating socio-economic and health impacts worldwide. This highlights the fact that CoVs continue to evolve and have the genetic flexibility to become highly pathogenic in humans and other mammals. SARS-CoV-2 carries a high genetic homology to the previously identified CoV (SARS-CoV), and the immunological and pathogenic characteristics of SARS-CoV-2, SARS-CoV, and MERS contain key similarities and differences that can guide therapy and management. This review presents salient and updated information on comparative pathology, molecular pathogenicity, immunological features, and genetic characterization of SARS-CoV, MERS-CoV, and SARS-CoV-2; this can help in the design of more effective vaccines and therapeutics for countering these pathogenic CoVs.PMID:34859882 | DOI:10.26355/eurrev_202111_27...
Source: Pharmacological Reviews - Category: Drugs & Pharmacology Authors: Source Type: research

Related Links:

Dr Maria Bottazzi says their vaccine, called Corbevax, is unique because they do not intend to patent itA new Covid-19 vaccine is being developed by Texas scientists using a decades-old conventional method that will make the production and distribution cheaper and more accessible for countries most affected by the pandemic and where new variants are likely to originate due to low inoculation rates.The team, led by Drs Peter Hotez and Maria Bottazzi from the Texas Children ’s Hospital Center for Vaccine Development at Baylor College of Medicine, has been developing vaccine prototypes for Sars and Mers since 2011, whic...
Source: Guardian Unlimited Science - Category: Science Authors: Tags: Texas Coronavirus Vaccines and immunisation US news World news Science Source Type: news
This article summarizes the current pandemic, different strains of SARS-CoV-2, etiology, complexities, surviving medications of COVID-19, and so far, vaccination for the treatment of COVID-19.PMID:34959116 | PMC:PMC8673752 | DOI:10.1016/j.biopha.2021.112550
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - Category: Drugs & Pharmacology Authors: Source Type: research
FINDINGSResearchers at the  Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA have identified rare, naturally occurring T cells that are capable of targeting a protein found in SARS-CoV-2 and a range of other coronaviruses.The findings suggest that a component of this protein, called viral polymerase, could potentially be added to COVID-19 vaccines to create a longer-lasting immune response and increase protection against new variants of the virus.BACKGROUNDMost COVID-19 vaccines use part of the spike protein found on the surface of the virus to prompt the immune system to produc...
Source: UCLA Newsroom: Health Sciences - Category: Universities & Medical Training Source Type: news
Eur Rev Med Pharmacol Sci. 2021 Nov;25(22):7162-7184. doi: 10.26355/eurrev_202111_27270.ABSTRACTThe last two decades have witnessed the emergence of three deadly coronaviruses (CoVs) in humans: severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). There are still no reliable and efficient therapeutics to manage the devastating consequences of these CoVs. Of these, SARS-CoV-2, the cause of the currently ongoing coronavirus disease 2019 (COVID-19) pandemic, has posed great global health concerns. The...
Source: Pharmacological Reviews - Category: Drugs & Pharmacology Authors: Source Type: research
Biophys J. 2021 Nov 9:S0006-3495(21)00956-5. doi: 10.1016/j.bpj.2021.11.009. Online ahead of print.ABSTRACTThe ongoing COVID-19 pandemic is a global public health emergency requiring urgent development of efficacious vaccines. While concentrated research efforts are underway to develop antibody-based vaccines that would neutralize SARS-CoV-2, and several first-generation vaccine candidates are currently in Phase III clinical trials or have received emergency use authorization, it is forecasted that COVID-19 will become an endemic disease requiring second-generation vaccines. The SARS-CoV-2 surface Spike (S) glycoprotein re...
Source: Biophysical Journal - Category: Physics Authors: Source Type: research
Tahmina Shirin Diverse coronavirus (CoV) strains can infect both humans and animals and produce various diseases. CoVs have caused three epidemics and pandemics in the last two decades, and caused a severe impact on public health and the global economy. Therefore, it is of utmost importance to understand the emergence and evolution of endemic and emerging CoV diversity in humans and animals. For diverse bird species, the Infectious Bronchitis Virus is a significant one, whereas feline enteric and canine coronavirus, recombined to produce feline infectious peritonitis virus, infects wild cats. Bovine and canine CoVs ha...
Source: Viruses - Category: Virology Authors: Tags: Review Source Type: research
Comp Med. 2021 Sep 17. doi: 10.30802/AALAS-CM-21-000011. Online ahead of print.ABSTRACTThe coronavirus disease 2019 (COVID-19) pandemic was caused by a novel coronavirus, severe acute respiratory syndromecoronavirus 2 (SARS-CoV-2). This virus has challenged civilization and modern science in ways that few infectious diseases and natural disasters have previously, causing globally significant human morbidity and mortality and triggering economic downturns across financial markets that will be dealt with for generations. Despite this, the pandemic has also brought an opportunity for humanity to come together and participate ...
Source: Comparative Medicine - Category: Zoology Authors: Source Type: research
DiscussionThis review discusses the pharmacological/clinical background and questions the rationale and study design of clinical trials with already approved HIV protease inhibitors and nucleos(t)ide RNA polymerase inhibitors which are repositioned during the SARS-CoV-2 pandemic worldwide. Proposals are made for future study design and drug repositioning of approved antiretroviral compounds.
Source: European Journal of Clinical Pharmacology - Category: Drugs & Pharmacology Source Type: research
Curr Med Chem. 2021 May 21. doi: 10.2174/0929867328666210521164809. Online ahead of print.ABSTRACTThe aim of this review article is to summarize the knowledge available to date on prophylaxis achievements to fight against Coronavirus. This work will give an overview of what is reported in the most recent literature on vaccines (under investigation or already developed like BNT162b2, mRNA-1273, and ChAdOx1-S) effective against the most pathogenic Coronaviruses (SARS-CoV-1, MERS-CoV-1, and SARS-CoV-2), with of course particular attention paid to those under development or already in use to combat the current COVID-19 (COrona...
Source: Current Medicinal Chemistry - Category: Chemistry Authors: Source Type: research
More News: Allergy & Immunology | Coronavirus | COVID-19 | Drugs & Pharmacology | Genetics | MERS | Middle East Health | Pandemics | Pathology | Respiratory Medicine | SARS | Vaccines